Titre :

Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin''s lymphoma.

Auteur(s) :

Barbieux, S [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Boyle, Eileen [Auteur]
Hôpital Claude Huriez [Lille]
Baillet, Clio [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Demarquette, Helene [Auteur]
Hôpital Claude Huriez [Lille]
Vermersch, Patrick [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Herbaux, Charles [Auteur]

Titre de la revue :

Current research in translational medicine

Nom court de la revue :

Curr. Res. Transl. Med.

Numéro :

66

Pagination :

87-89

Date de publication :

2018-07-04

ISSN :

2452-3186

Mot(s)-clé(s) :

Hodgkin''s lymphoma
Polyradiculopathy
Idelalisib

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with standard treatment. Idelalisib, a delta-isoform specific Phosphatidyl-inositol-3-kinase (PI3K) inhibitor has shown its efficacy in other ...
Lire la suite >Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with standard treatment. Idelalisib, a delta-isoform specific Phosphatidyl-inositol-3-kinase (PI3K) inhibitor has shown its efficacy in other hematopoietic B malignancies. We report the case of a 51-years old patient with relapsed and refractory Hodgkin's Lymphoma receiving idelalisib after several regimens of chemotherapy. He achieved a good partial response for several months, unfortunately, idelalisib had to be stopped because of the onset of a severe polyradiculoneuritis attributed to this treatment. We assume here that the polyradiculoneuritis could be caused by T cell mediated autoimmunity to myelin proteins. To our knowledge, this adverse event has never been described so far with idelalisib.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Inserm

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables
Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-02-26T17:06:50Z
2022-01-12T11:20:22Z